Françoise Grudé

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study

Hugues Bourgeois, Françoise Grudé, P. Solal-Céligny et al. · Annals of Oncology · 2017 · 47 citations · Full text

Prognostic Assessment, Medicine, Cancer Management +10

PANERB study: Panitumumab after cetuximab-based regimen failure.

J-P. Metges, Jean‐Luc Raoul, Nacredine Achour et al. · Journal of Clinical Oncology · 2010 · 38 citations

Panerb Study, Medicine, Cancer Management +11

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Emmanuelle Jacquet, Ghania Kerouani‐Lafaye, Françoise Grudé et al. · European Journal of Cancer · 2021 · 16 citations · Full text

Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer.

Jean Philippe Metges, Jean François Ramée, Jean‐Yves Douillard et al. · Journal of Clinical Oncology · 2014 · 13 citations

Surgical Oncology, Cancer Management, Gastroenterology +22

Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019

Fiona Y.‐V. Pham, Emmanuelle Jacquet, Amina Taleb et al. · International Journal of Cancer · 2022 · 11 citations · Full text

Therapeutic Benefit, Temporary Authorization, Solid Tumors +20